SciBX: Science-Business eXchange Contents: June 21 2012, Volume 5 / Issue 25

TABLE OF CONTENTS June 21 2012, Volume 5 / Issue 25 Analysis Cover Story Targets and Mechanisms The Distillery: Therapeutics Cancer Endocrine/metabolic disease Infectious disease Inflammation Neurology The Distillery: Techniques Chemistry Disease models Drug delivery Knome provides researchers and clinics with human whole genome interpretation software and services. Visit www.knome.com to learn how we can help you identify the variants, genes, and gene sets that underlie disease and drug response.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Bringing patient data into the open Joanne Kotz doi:10.1038/scibx.2012.644 Two groups have come to the conclusion that breakthroughs in translational medicine require collecting large-scale data on patients, including outcomes, and making those data available to translational researchers. Sage Bionetworks launched a portal through which users can contribute their own health and genomic data for research, and a report from the U.S. National Academy of Sciences is calling for the creation of a national infrastructure for accessing and analyzing open-source patient data. Full Text | PDF Top GSK completes its Canadian tripod Michael J. Haas doi:10.1038/scibx.2012.645 GlaxoSmithKline has announced its third major academic collaboration in Canada in the past two years—a deal with the Centre for Drug Research and Development to identify and fund academic research in the country. Full Text | PDF Targets and Mechanisms Top Reining in pain Lev Osherovich doi:10.1038/scibx.2012.646 UCSF researchers have shown that neuronal precursor cells from fetal mouse brains can be transplanted into the spinal cord of adult mice to treat neuropathic pain. The embryonic brain cells are being developed by Neurona. Full Text | PDF ADORAble implants Kai-Jye Lou doi:10.1038/scibx.2012.647 NYU researchers have shown that adenosine A2A receptor agonists can block the inflammation and bone destruction that stems from debris flaking off joint implants, a leading cause of implant failure. The group now needs to translate the findings into a product that companies can test in the clinic. Full Text | PDF Distillery: Therapeutics Cancer Top CC chemokine receptor 5 (CCR5; CD195) doi:10.1038/scibx.2012.648 In vitro and mouse studies suggest CCR5 antagonists could help prevent breast cancer metastasis. Full Text | PDF Ataxia telangiectasia mutated (ATM); c-Met proto-oncogene (MET; HGFR); p53 doi:10.1038/scibx.2012.649 Computational pathway analysis and a cell-based genomewide small hairpin RNA screen suggest inhibition of ATM or MET could improve the efficacy of the small molecule p53 pathway activator Nutlin-3 in cancer. Full Text | PDF BCL2-associated X protein (BAX) doi:10.1038/scibx.2012.650 An in vitro and cell culture study identified a small molecule activator of the proapoptotic B cell lymphoma 2 (BCL-2; BCL2) family member BAX that could help treat cancer. Full Text | PDF Guanine nucleotide binding protein β-polypeptide 2-like 1 (GNB2L1; RACK1) doi:10.1038/scibx.2012.651 Patient sample and mouse studies suggest inhibiting RACK1 could help treat hepatocellular carcinoma (HCC). Full Text | PDF Forkhead box O1 (FOXO1); epidermal growth factor receptor (EGFR) doi:10.1038/scibx.2012.652 Studies in cell culture and in mice suggest trifluoperazine hydrochloride (TFP) could help restore the sensitivity of lung cancer to EGFR-targeting therapies. Full Text | PDF MAP kinase kinase kinase 7 (MAP3K7; TAK1) doi:10.1038/scibx.2012.653 In vitro studies suggest TAK1 inhibitors could help treat lymphoma. Full Text | PDF Endocrine/metabolic disease Top G protein–coupled receptor 21 (GPR21) doi:10.1038/scibx.2012.654 Mouse studies suggest inhibiting GPR21 could help treat or prevent type 2 diabetes. Full Text | PDF Agouti related protein (AGRP); forkhead box O1 (FOXO1); G protein–coupled receptor 17 (GPR17) doi:10.1038/scibx.2012.655 Mouse and in vitro studies suggest inhibiting FOXO1-GPR17 signaling could help treat obesity. Full Text | PDF Infectious disease Top Ebola glycoprotein GP1; Ebola glycoprotein GP2 doi:10.1038/scibx.2012.656 Nonhuman primate studies suggest a mAb-based treatment could help improve survival after an Ebola infection. Full Text | PDF Platelet factor 4 (PF4; CXCL4) doi:10.1038/scibx.2012.657 Cell culture studies suggest CXCL4 could help prevent HIV replication. Full Text | PDF Inflammation Top Periostin (POSTN) doi:10.1038/scibx.2012.658 In vitro and mouse studies suggest blocking POSTN could help treat atopic dermatitis. Full Text | PDF Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP); toll-like receptor 4 (TLR4); TLR2; tumor necrosis factor-α (TNF-α); IL-6 doi:10.1038/scibx.2012.659 In vitro and mouse studies suggest Tirap-derived peptides could help treat inflammatory disease. Full Text | PDF Neurology Top β-Amyloid (Aβ) doi:10.1038/scibx.2012.660 In vitro assays suggest conjugates of benzothiazole-based molecules and Cu2+ chelators could help treat AD. Full Text | PDF Sterile α and TIR motif containing 1 (SARM1) doi:10.1038/scibx.2012.661 In vitro, fly and mouse studies suggest inhibiting SARM1 could help prevent axon loss after injury. Full Text | PDF Thrombin (Factor IIa; F2) doi:10.1038/scibx.2012.662 Rat studies suggest detecting thrombin activity in the brain could help diagnose stroke and inhibiting thrombin during stroke could help reduce neurovascular damage. Full Text | PDF Distillery: Techniques Chemistry Top Combinatorial chemistry method for identifying boronic acid–based inhibitors of oxygenase enzymes doi:10.1038/scibx.2012.663 A combinatorial chemistry method for identifying boronic acid–based inhibitors of oxygenase enzymes could help identify new therapeutic leads. Full Text | PDF Disease models Top A mouse model of Gleevec-resistant gastrointestinal stromal tumors (GISTs) could aid the identification of new therapies doi:10.1038/scibx.2012.664 A mouse model of Gleevec-resistant GIST could help identify new GIST therapies. Full Text | PDF In vitro microvasculature network model doi:10.1038/scibx.2012.665 An in vitro model of organ microvasculature could be useful for identifying compounds that target the vasculature to treat cardiovascular diseases. Full Text | PDF Mouse model of human mucosa associated lymphoma tissue (MALT) lymphoma doi:10.1038/scibx.2012.666 A MALT lymphoma model could be used to test therapeutics for the disease. Full Text | PDF Drug delivery Top Vaginal delivery of antiviral-loaded mucus-penetrating particles (MPPs) doi:10.1038/scibx.2012.667 Vaginal delivery of antiviral-loaded MPPs could be used to prevent viral infections. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.